Pivotal a rising star
Pivotal has been selected as one of the few firms that attracted recognition from the Pharma IQ network as a “RISING STAR”
We´re delighted to bring to your attention the results of the survey at: https://www.pharma-iq.com/regulatorylegal/articles/top-10-clinical-research-organisations-in-the#.WrtCW19Q98M.linkedin.
This survey was performed independently by Pharma IQ among their international community members who were asked to nominate CROs for 2018, which they recognized as the leading and the best in the pharmaceutical and biologics industry based on their own experiences. The research base is made up of international participants from mainly big pharma or biotechs, SME pharma and consultants, government bodies, medical device manufacturers and public hospitals.
It´s with utmost pride that we´d like to share with you that Pivotal was one of the few firms that attracted recognition from the Pharma IQ network as a “RISING STAR”. This category received significant amounts of votes from the respondents base and just fell outside the top 10 rank.
This is very much related to your continued confidence and trust in Pivotal as your valued partner in clinical research and the quality of services Pivotal provides across a broad spectrum of clinical trails and therapeutic areas.
Ms. Natalia Farr